Suggested remit: to appraise the clinical and cost effectiveness of pembrolizumab with chemoradiation within its marketing authorisation for untreated high-risk locally advanced cervical cancer.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6138
Provisional Schedule
- Committee meeting: 2:
- 10 March 2026
- Expected publication:
- 07 May 2026
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Merck Sharp & Dohme (pembrolizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- None
- Professional groups
- Association of Cancer Physicians
- British Gynaecological Cancer Society
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 February 2026 - 24 February 2026 | Draft guidance |
| 13 January 2026 | Committee meeting |
| 11 September 2025 | Awaiting development. Dear stakeholders, I am writing to inform you that NICE has revised the timelines for this evaluation. The committee meeting will now be held on 13 January 2026. Please note that the project team will reach out to nominated experts directly regarding availability for the new meeting date. |
| 12 August 2025 | Note - Note added to the project documents |
| 06 January 2025 | Invitation to participate |
| 09 December 2024 - 23 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 March 2024 | Note - Note added to the project documents |
| 28 December 2023 | Note - Note added to the project documents |
| 22 November 2023 - 20 December 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6138 |
| 28 June 2023 | Note - Note added to the project documents |
| 01 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 29 November 2022 | Note added to the project documents |
| 13 October 2022 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual